2025
Decoding Erdheim–Chester Disease: a Pictorial Essay of the Radiologic and Pathologic Findings, and its Main Differential Diagnoses
de Oliveira Santo I, Lerner G, Rubinowitz A, Fadel S, Chen M, Mojibian H, Mathur M. Decoding Erdheim–Chester Disease: a Pictorial Essay of the Radiologic and Pathologic Findings, and its Main Differential Diagnoses. Clinical Radiology 2025, 85: 106873. PMID: 40215805, DOI: 10.1016/j.crad.2025.106873.Peer-Reviewed Original ResearchConceptsErdheim-Chester diseaseManagement of Erdheim–Chester diseaseEvaluate disease extentMolecular mutation analysisClonal myeloid neoplasmsMonitoring Treatment ResponsePotential diagnostic pitfallsModern treatment strategiesPictorial essayDecades of lifeAffected organ systemsCentral nervous systemUnder-recognised conditionNonspecific presentationMyeloid neoplasmsDiagnostic suspicionDisease extentRadiological findingsTargeted therapyFoamy histiocytesClinical featuresPI3K-Akt pathwayDiagnostic pitfallsHistiocytic neoplasmsImaging findings
2023
Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms
Stempel J, Xie Z, Bewersdorf J, Stahl M, Zeidan A. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms. The Cancer Journal 2023, 29: 203-211. PMID: 37195777, DOI: 10.1097/ppo.0000000000000666.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInternational Working Group response criteriaResponse criteriaPhase III clinical trialsIWG 2006 criteriaRisk of progressionPatient-focused outcomesClonal myeloid neoplasmsAcute myeloid leukemiaTherapeutic response assessmentPatient-centered responsesNovel drug developmentHematologic recoveryProgressive cytopeniasClinical trialsIWG criteriaLong-term benefitsMyeloid leukemiaIneffective hematopoiesisMyeloid neoplasmsResponse assessmentDisease severity
2017
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications
Stahl M, Zeidan AM. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer 2017, 123: 1703-1713. PMID: 28192601, DOI: 10.1002/cncr.30585.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaProlong survivalLow-risk MDSLR-MDS patientsEfficacy of lenalidomideImpressive clinical activityRecent clinical dataClonal myeloid neoplasmsMechanism of actionBlood cytopeniasConventional careTransfusion independenceCytogenetic responseClinical activityMyeloid leukemiaClinical dataIneffective hematopoiesisMyeloid neoplasmsDelay progressionHigh riskLenalidomidePatientsVariable riskHeterogeneous groupProgression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply